BTK and atopic eczema: Since concentrations required for blocking histamine release were significantly lower than for blocking proliferation and survival, ibrutinib may also have clinical implications for other IgE‐dependent diseases in dogs, such as canine atopic dermatitis or food allergies.54, 55, 56, 57 Our findings are reinforced by previous data showing that BTK is expressed in human BAs and MCs and that BTK inhibition by ibrutinib is associated with reduced IgE‐dependent mediator release in these cells.23, 24, 25, 26, 27